



doi.org/10.51891/rease.v10i8.15396

UNRAVELING THE GENETIC AND EPIGENETIC LANDSCAPE OF RHEUMATOID ARTHRITIS: A COMPREHENSIVE REVIEW OF PATHOGENESIS, DIAGNOSIS, AND THERAPEUTIC IMPLICATIONS

Juliana Coimbra de Mendonça¹ Mariana Melo Almeida² Francesco Maronese³ Afrânio Côgo Destefani⁴ Vinícius Côgo Destefani⁵

ABSTRACT: This exhaustive review delves into the genetic and epigenetic foundations of Rheumatoid Arthritis (RA), a multifaceted autoimmune disorder characterized by persistent joint inflammation. We discuss the findings of genome-wide association studies (GWAS) that have uncovered numerous genetic loci associated with RA, emphasizing the substantial impact of HLA variants on disease susceptibility and severity. The review also explores epigenetic mechanisms such as DNA methylation, histone modifications, and the regulatory role of microRNAs, all of which influence gene expression and immune response in RA. The involvement of inflammasomes in mediating inflammatory responses emphasizes potential therapeutic targets. Furthermore, the application of artificial intelligence for analyzing intricate genetic data presents promising opportunities for advancing diagnosis and treatment strategies. This article underscores the critical need for integrating multi-omics data. It emphasizes the significance of collaborative research in the field of RA, highlighting the importance of your work in this area.

Keywords: Rheumatoid Arthritis. Genetic Predisposition to Disease. Epigenomics. Inflammasomes. Artificial Intelligence.

INTRODUCTION

Rheumatoid arthritis (RA) is a complex autoimmune disease characterized by chronic inflammation and progressive joint destruction. Despite significant advancements in understanding the pathogenesis of RA, the exact etiology still needs to be discovered. In recent years, genetic and epigenetic studies have revolutionized our understanding of the molecular mechanisms underlying RA, paving the way for novel diagnostic and therapeutic approaches. This comprehensive review aims to summarize the current knowledge regarding RA's genetic

¹Faculdade de Medicina de Barbacena.

²Centro Universitário Unifaminas.

³Universidade de Ribeirão Preto (UNAERP - Campus Ribeirão Preto).

⁴Santa Casa de Misericórdia de Vitoria Higher School of Sciences - EMESCAM. Santa Luíza - Vitória - ES - Brazil Molecular Dynamics and Modeling Laboratory (DynMolLab).

Molecular Dynamics and Modeling Laboratory (DynMolLab) Santa Luíza - Vitória -ES - Brazil.





and epigenetic landscape, highlighting the revolutionary impact of these studies and the optimistic future they promise for disease pathogenesis, diagnosis, and treatment.

METHODOLOGY

A systematic literature search was conducted using PubMed, Scopus, Web of Science, and ScienceDirect databases. The search terms included "rheumatoid arthritis," "genetics," "epigenetics," "genomics," "microRNA," "inflammasome," and "artificial intelligence." Relevant articles published in English from 2010 to 2023 were selected based on their methodological quality and impact on the field. The selected articles were critically appraised, and critical findings were synthesized to provide a comprehensive overview of RA's genetic and epigenetic landscape.

RESULTS

Genetic Architecture of Rheumatoid Arthritis

I.I. Genome-Wide Association Studies (GWAS)

Genome-wide association studies have identified over 100 genetic loci associated with RA susceptibility (1). These loci, particularly the HLA region, collectively explain approximately 20% of the genetic heritability of RA, with the HLA region accounting for the most significant proportion of genetic risk. (2). Most RA-associated variants are in non-coding regions, suggesting a regulatory role in gene expression (3).

1.2. HLA Variants and RA Risk

The HLA region, particularly the HLA-DRBI locus, has been consistently associated with RA risk across different populations (4). Specific HLA-DRBI alleles, known as shared epitope (SE) alleles, confer a higher risk of developing RA and are associated with more severe disease outcomes (4). The SE hypothesis suggests that these alleles share a typical amino acid sequence that facilitates the presentation of arthritogenic peptides to T cells, triggering an autoimmune response (5).





1.3. Non-HLA Genetic Variants

Non-HLA genetic variants, in addition to the HLA region, have been implicated in RA pathogenesis. These variants involve various immune-related pathways, such as T-cell activation, B-cell function, and cytokine signaling. (2). Notable examples include variants in the PTPN22, STAT4, and TRAF1-C5 loci, which have been consistently associated with RA risk across multiple studies (6,7).

Epigenetic Mechanisms in Rheumatoid Arthritis

2.1. DNA Methylation

DNA methylation, an epigenetic modification that regulates gene expression, has been implicated in the pathogenesis of RA (8). Genome-wide methylation studies have identified differentially methylated regions (DMRs) in immune-related genes, such as IL6R, IFNG, and FOXP3, in RA patients compared to healthy controls (9). These DMRs may contribute to the dysregulation of immune responses and the perpetuation of inflammation in RA (10).

2.2. Histone Modifications

3383

Histone modifications, such as acetylation and methylation, are crucial in regulating gene expression and have been implicated in RA pathogenesis (II). Altered histone modification patterns have been observed in RA synovial fibroblasts, leading to the overexpression of pro-inflammatory genes and the promotion of joint destruction (II). Targeting histone-modifying enzymes, such as histone deacetylases (HDACs), has emerged as a potential therapeutic strategy for RA (I2).

2.3. MicroRNAs

MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression post-transcriptionally and have been implicated in the pathogenesis of RA (13). Altered miRNA expression profiles have been observed in various cell types and tissues involved in RA, such as synovial fibroblasts, T cells, and plasma. Specific miRNAs, such as miR-146a and miR-155, have modulated RA inflammatory responses and disease activity. miRNAs have





emerged as potential biomarkers for disease diagnosis, prognosis, and treatment response prediction in RA (14).

Inflammasomes in Rheumatoid Arthritis

Inflammasomes are multiprotein complexes that play a critical role in the innate immune response by regulating the activation of caspase-1 and the processing of proinflammatory cytokines, such as IL-1β and IL-18 (15,16). The NLRP3 inflammasome has been particularly implicated in the pathogenesis of RA, with increased expression and activation observed in the synovial tissue and peripheral blood mononuclear cells of RA patients (17). Targeting inflammasome components, such as NLRP3 and caspase-1, has shown promise as a therapeutic strategy for RA in preclinical studies (15).

Artificial Intelligence in Rheumatology

Artificial intelligence (AI) techniques, such as machine learning and deep learning, have emerged as powerful tools for analyzing large-scale genetic and epigenetic data in RA, offering promising avenues for advancing diagnosis and treatment strategies (18). AI algorithms can identify complex patterns and interactions between genetic variants, epigenetic modifications, and clinical phenotypes, enabling the development of predictive models for disease risk, progression, and treatment response (19). More importantly, AI-based approaches have also been applied to imaging data, such as radiographs and ultrasound scans, to significantly improve the accuracy and efficiency of disease diagnosis and monitoring in RA, offering hope and reassurance for the future of RA management (20).

DISCUSSION

RA's genetic and epigenetic landscape is complex and multifaceted, involving multiple genetic variants, epigenetic modifications, and environmental factors. Advances in genomic technologies and analytical methods have greatly expanded our understanding of the molecular mechanisms underlying RA pathogenesis. Genetic studies have identified numerous risk loci and highlighted the central role of the HLA region in RA susceptibility. Epigenetic studies have revealed the importance of DNA methylation, histone modifications, and miRNAs in





regulating gene expression and immune responses in RA. The discovery of inflammasomes has provided new insights into the innate immune mechanisms driving inflammation and joint damage in RA.

Despite these significant advancements, several challenges remain in translating genetic and epigenetic findings into clinical practice. Most RA-associated variants have small effect sizes and may interact with each other and environmental factors in complex ways. The functional consequences of many genetic and epigenetic alterations remain to be elucidated, requiring further functional studies and multi-omics data integration. The development of AI-based approaches holds promise for uncovering novel insights and improving disease diagnosis and management. Still, data quality, interpretability, and ethical considerations need to be addressed.

CONCLUSION

RA's genetic and epigenetic landscape rapidly evolves, providing new insights into disease pathogenesis and potential therapeutic targets. Integrating genetic, epigenetic, and clinical data using advanced analytical methods like AI will be crucial for developing personalized approaches to RA diagnosis, prognosis, and treatment. Future research should focus on elucidating the functional consequences of genetic and epigenetic alterations, validating biomarkers for clinical use, and developing targeted therapies that address the underlying molecular mechanisms of RA. By harnessing the power of genomics and epigenomics, we can move towards a more precise and effective management of RA, ultimately improving patient outcomes and quality of life.

REFERENCES

1.OKADA Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488).

2.EYRE S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44(12).

3.KIM K, Bang SY, Lee HS, Bae SC. Update on the genetic architecture of rheumatoid arthritis. Vol. 13, Nature Reviews Rheumatology. 2017.





4.RAYCHAUDHURI S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3).

5.TAN LK, Too CL, Diaz-Gallo LM, Wahinuddin S, Lau IS, Heselynn H, et al. The spectrum of association in HLA region with rheumatoid arthritis in a diverse Asian population: evidence from the MyEIRA case-control study. Arthritis Res Ther. 2021;23(1).

6.ZHERNAKOVA A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011;7(2).

7.OKADA Y, Suzuki A, Ikari K, Terao C, Kochi Y, Ohmura K, et al. Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. Am J Hum Genet. 2016;99(2).

8.LIU Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31(2).

9.ARAKI Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. Vol. 18, International Journal of Molecular Sciences. 2017.

10.NEMTSOVA M V., Zaletaev D V., Bure I V., Mikhaylenko DS, Kuznetsova EB, Alekseeva EA, et al. Epigenetic changes in the pathogenesis of rheumatoid arthritis. Vol. 10, Frontiers in Genetics. 2019.

3386

II.KLEIN K, Ospelt C, Gay S. Epigenetic contributions in the development of rheumatoid arthritis. Vol. 14, Arthritis Research and Therapy. 2012.

12.HUI L, Ziyue Z, Chao L, Bin Y, Aoyu L, Haijing W. Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine. Vol. 53, European Journal of Immunology. 2023.

13. VICENTE R, Noël D, Pers YM, Apparailly F, Jorgensen C. Deregulation and therapeutic potential of microRNAs in arthritic diseases. Vol. 12, Nature Reviews Rheumatology. 2016.

14.EVANGELATOS G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Vol. 18, Autoimmunity Reviews. 2019.

15.MATHEWS RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); Genetic variants within the NLRP3-inflammasome complex about susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73(6).





16.MAKKAR R, Behl T, Bungau S, Kumar A, Arora S. Understanding the Role of Inflammasomes in Rheumatoid Arthritis. Vol. 43, Inflammation. 2020.

17.JIANG Q, Wang X, Xu X, Hu L, Zhou G, Liu R, et al. Inflammasomes in rheumatoid arthritis: a pilot study. BMC Rheumatol. 2023;7(1).

18.OBERMEYER Z, Emanuel EJ. Predicting the Future — Big Data, Machine Learning, and Clinical Medicine. New England Journal of Medicine. 2016;375(13).

19.HÜGLE M, Omoumi P, van Laar JM, Boedecker J, Hügle T. Applied machine learning and artificial intelligence in rheumatology. Vol. 4, Rheumatology Advances in Practice. 2021.

20.CHANDWAR K, Misra DP. What does artificial intelligence mean in rheumatology? Vol. 39, Archives of Rheumatology. 2024.